- Home
- DRUG vs LEGT Comparison
DRUG vs LEGT Comparison
Compare DRUG & LEGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRUG
- LEGT
- Stock Information
- Founded
- DRUG 2019
- LEGT 2023
- Country
- DRUG United States
- LEGT United States
- Employees
- DRUG N/A
- LEGT N/A
- Industry
- DRUG Pharmaceuticals and Biotechnology
- LEGT
- Sector
- DRUG Health Care
- LEGT
- Exchange
- DRUG Nasdaq
- LEGT Nasdaq
- Market Cap
- DRUG 345.6M
- LEGT 276.8M
- IPO Year
- DRUG N/A
- LEGT 2024
- Fundamental
- Price
- DRUG $45.43
- LEGT $10.77
- Analyst Decision
- DRUG Strong Buy
- LEGT
- Analyst Count
- DRUG 9
- LEGT 0
- Target Price
- DRUG $81.67
- LEGT N/A
- AVG Volume (30 Days)
- DRUG 70.6K
- LEGT 22.0K
- Earning Date
- DRUG 08-11-2025
- LEGT 01-01-0001
- Dividend Yield
- DRUG N/A
- LEGT N/A
- EPS Growth
- DRUG N/A
- LEGT N/A
- EPS
- DRUG N/A
- LEGT 0.35
- Revenue
- DRUG N/A
- LEGT N/A
- Revenue This Year
- DRUG N/A
- LEGT N/A
- Revenue Next Year
- DRUG N/A
- LEGT N/A
- P/E Ratio
- DRUG N/A
- LEGT $30.68
- Revenue Growth
- DRUG N/A
- LEGT N/A
- 52 Week Low
- DRUG $0.94
- LEGT $10.18
- 52 Week High
- DRUG $79.02
- LEGT $10.86
- Technical
- Relative Strength Index (RSI)
- DRUG 57.15
- LEGT 61.22
- Support Level
- DRUG $39.70
- LEGT $10.72
- Resistance Level
- DRUG $49.49
- LEGT $10.74
- Average True Range (ATR)
- DRUG 3.14
- LEGT 0.01
- MACD
- DRUG 0.13
- LEGT 0.00
- Stochastic Oscillator
- DRUG 64.66
- LEGT 83.33
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
About LEGT Legato Merger Corp. III
Legato Merger Corp III is a blank check company.